Opinion on  Ingen Technologies Inc (IGNT)
Annual Revenues expected to Air out the Competition

Projected annual sales potentials of the new Oxyview Nasal Cannula are $200M.

"We are excited about the new ad saturation campaign of our Oxyview Nasal Cannula for the millions of COPD patients and physicians.

These patients have been using 2-4 nasal cannulas a month during oxygen therapy. The therapy normally lasts the rest of their lives. The conventional style cannulas do not provide verification of oxygen flow rate, and the patients must rely on the equipment functionality.

The new Oxyview Nasal Cannula provides the home oxygen patients with a quality nasal cannula and in-line oxygen flow meter that provides an accurate reading of oxygen flow rate and a tremendous amount of confidence for the patients and physicians," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

  <font> http://moneycentral.msn.com/news/ticker/sigdev.aspx?Symbol=US... </font>